Recon: States name 26 generic drugmakers in price fixing suit; Novo to buy Corvidia for up to $2.1B

• States Sue Drug Companies, Executives Over Alleged Price Fixing (WSJ) (Reuters) (STAT)
• AstraZeneca ties up with Emergent BioSolutions to make COVID-19 vaccine in US (Reuters)
• Lilly COVID-19 treatment could be authorized for use as soon as September: chief scientist (Reuters)
• Regeneron begins human testing of COVID-19 antibody cocktail (Reuters) (WSJ)
• Pfizer says it won't put "huge price" on coronavirus vaccine (Axios)
• New York charges Endo with insurance fraud over opioid claims (Reuters)
• NIH launches study to assess drugs for coronavirus-affected children in US (Reuters)
• Quarantine fatigue: Governors reject new lockdowns as virus cases spike (Politico)
• U.S. coronavirus cases now over 2 million (Reuters)
• New report underscores the recent roller coaster of the biotech market (STAT)
• Trump’s decision to leave WHO came with bluster, but no action so far (STAT)

• Novo Nordisk to Buy Corvidia for as Much as $2.1 Billion (Bloomberg) (Endpoints) (Press)
• EU plans advance purchase of up to six promising COVID-19 vaccines: sources (Reuters)
• Europe sets sights on dud antibody tests amid COVID-19 free-for-all (Reuters)
• China offering coronavirus candidate vaccines to state workers, Global Times says (Reuters)
• Outbreak quashed, China launches test lab spending spree (Reuters)
• Japan's Takeda to sell some Asia-focused drugs to Celltrion for $278 million (Reuters) (Endpoints)
• Only French victims of faulty breast implant may claim damages, EU court says (Reuters)
• Russia rolls out first approved COVID-19 drug as infections pass 500,000 (Reuters)
• WHO warns of 'accelerating' pandemic in Africa (Politico) (Reuters) (WHO)
• WHO hopes to work with U.S. on Ebola despite Trump criticism (Reuters)

• The Big-Data Mystery Behind Retracted Covid-19 Studies of Hydroxychloroquine, Other Drugs (WSJ)
• IMF says $10 trillion spent to combat pandemic, far more needed (Reuters)
• Seattle’s coronavirus surveillance program resumes after being shut down by the FDA (Seattle Times)
• Pfizer partner BioNTech scores €100M debt financing to fund COVID-19 vaccine production in Europe (Fierce)
• India lifts export ban on Trump-touted drug hydroxychloroquine (Reuters)
• South Korean doctors find risk factors for severe COVID-19 cases (Reuters)
• Researchers Are Looking Into Alternatives To Remdesivir In The Coronavirus Treatment (NPR)

• Lonza partners with Anthos Therapeutics for thrombosis treatment (Reuters)
• Pharma's May TV ad spend dips as marketers find new normal (Fierce)
• Lilly starts large-scale trial of tirzepatide in diabetic heart disease (PMLive)
• Two preclinical biotechs riding the IPO wave this week look to raise $466M-plus; Blackstone's Galakatos backs Reata to the tune of $350M (Endpoints)
• A patient’s microbiome could have a major impact on how drugs affect them, new research confirms (STAT)
• Verve, raising another $63 million, seeks to advance gene-editing treatment for heart disease (STAT) (Endpoints)
• Juno, WuXi JV in China score $100M in fresh funding as it sets stage for first CAR-T approval (Endpoints)
• A storied Chinese pharma partner of Bristol Myers, Amgen — and avid biotech supporter — plots HK IPO (Endpoints)
• Rare Disease Therapy Development and Access Remain Top FDA Priorities During COVID-19 (FDA)
• FDA data shows numerous drugs in shortage, including a leading antidepressant (USA Today)
• The Vaccines for Children Program at 25 — Access, Affordability, and Sustainability (NEJM)
• Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria (NEJM, Commentary)
• Bone Drugs May Have Added Benefit: Lower Pneumonia Risk (NYTimes)
• Perelman’s Discount Drug Company Said to Weigh Sale Interest (Bloomberg)

• MedTech Europe pitches virtual audits to clear MDR coronavirus logjam (MedtechDive)
• EU MDR Standards Delay: MedTech Europe Offers A Pragmatic Way Forward (MedtechInsight)
• Denmark’s Møller Named Executive Board Chair At Medical Device Competent Authorities Group (MedtechInsight)
• Short-term ventilator sharing may be viable for COVID-19 patients: study (Reuters)
• COVID-19 testing costs may hit $25B per year, AHIP study finds (MedtechDive)
• Philips launches Lumify tele-ultrasound system in Japan (MassDevice)

• California supports an attorney’s unusual whistleblower lawsuit against ‘fraudulent’ patents (STAT)
• COVID-19 Vaccine Developers Can Limit Liability From Trials (Law360)
• Tuesdays (and Thursdays) With Regulations.gov BETA (FDA Law Blog)
• A Loss, But Not Much of One (Drug & Device Law)